X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

Tycko & Zavareei LLP Scores Appellate Victory on Behalf of APA Membership

Yuvraj_pawp by Yuvraj_pawp
5th September 2014
in Market Moves

Tycko & Zavareei has scored a significant appellate victory on behalf of the membership of the American Psychological Association (“APA”). On September 5, 2014, the United States Court of Appeals for the D.C. Circuit reversed the trial court’s dismissal of a class action complaint alleging improper dues-charging practices by the APA, in Levine et al. v. American Psychological Association and American Psychological Association Practice Organization. The decision was authored by Circuit Judge Sri Srinivasan on behalf of a unanimous panel that also included Circuit Judges Judith Rogers and Thomas Griffith.

 

In their class action complaint, members of the APA—represented by Tycko & Zavareei—alleged that the APA falsely represented to its members (on its annual dues statements and elsewhere) that they were required to pay an annual “practice assessment” for continued APA membership. According to the lawsuit, payment of the assessment was not, in fact, a condition of APA membership. Rather, the APA funneled these funds to its lobbying arm: the American Psychological Association Practice Organization (“APAPO”). The plaintiffs asserted that the APA did this because it did not believe that its members would voluntarily donate sufficient funds to the APAPO to support its lobbying activities; however, it could not mandate payment of funds for lobbying purposes as a condition of membership without jeopardizing its tax-exempt status as a 501(c)(3) charitable organization under the Internal Revenue Code. Thus, the APA allegedly tried to have it both ways: by falsely representing in its communications to its members that payment of the practice assessment was a condition of APA membership to obtain funding for the APAPO, but not making payment of the assessment an official membership requirement to avoid potentially losing its federal tax-exempt status.

 

The D.C. Circuit disagreed with the trial court’s conclusion that the plaintiffs failed to state viable legal claims. Namely, the court reversed the dismissal of claims against the APA for unjust enrichment and also disagreed with the trial court’s conclusion that the plaintiffs could not amend their complaint to state a claim for fraudulent inducement on the grounds that any amendment could be futile. Finally, the D.C. Circuit held that the plaintiffs were free to move for leave to amend their complaint to add a cause of action for negligent misrepresentation.

 

In its decision, the D.C. Circuit held that plaintiffs adequately alleged that the APA “included misleading language on the dues statement in order to deceive plaintiffs into overpaying for APA membership.” In assessing the case, the court observed that “the dues statement contained several indications that payment of the special assessment was a requirement of APA membership.” The court also observed that in light of plaintiffs’ allegations that the APA website did not allow payment of dues without payment of the special assessment, “[a] member who viewed the dues statement in conjunction with the website therefore had even greater reason to believe that payment of the special assessment was a condition of APA membership.” In the face of the APA’s contention that despite the misleading language on the dues statements, plaintiffs should have investigated further before paying what they thought was required, the D.C. Circuit panel disagreed, stating that “plaintiffs reasonably could have concluded that the meaning of the dues statement was clear, such that there was no reason to investigate further.”

 

Lead attorney for the plaintiffs, Hassan Zavareei, explained, “This decision by the DC Circuit establishes the basis for a nationwide class against the APA for its deceptive charges of its own members. We are pleased that the case can now proceed so that we can seek restitution for the thousands of psychologists who were duped into paying hundreds of dollars for controversial lobbying efforts by the APA lobbying entity.” The case will now be remanded to the United States District Court for the District of Columbia for further proceedings. The plaintiffs were also represented by Wexler Wallace, LLP, Miller Law Firm, P.C., Greg Coleman Law PC, and Whitfield Bryson & Mason LLP. In addition, Tycko & Zavareei represents the plaintiff in a related class action, Grossman v. American Psychological Association and American Psychological Association Practice Organization.

SOURCE Tycko & Zavareei LLP

Previous Post

Luye Pharma Acquired 57.98% Stake of Beijing Jialin Pharmaceutical

Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Related Posts

Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Market Moves

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

26th October 2021
My Personal Therapeutics and Pentavere receive EUREKA AI Therapeutics Funding to support the development of My Personal Therapeutics - digital therapeutics for Lung Cancer
Manufacturing

Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute

2nd August 2021
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

3rd December 2020
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Antares Vision acquires pharma packaging leak specialist for $17.9m

20th July 2020
Next Post

Astellas Receives Notification from FDA of Acceptance of Filing of Isavuconazole NDA for the Treatment of Invasive Aspergillosis and Invasive Mucormycosis

Latest News

NIH begins study of allergic reactions to Covid-19 vaccines
News

To Treat COVID WHO Approves Monoclonal Antibody Tocilizumab

18th February 2022
Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In